What is Insmed's stock-based comp?

Insmed (INSM) reported stock-based comp of $45.75M in Q1 2026.

How has Insmed's stock-based comp changed year-over-year?

Insmed's stock-based comp increased by 16.5% year-over-year, from $39.26M to $45.75M.

What is the long-term trend for Insmed's stock-based comp?

Over 4 years (2021 to 2025), Insmed's stock-based comp has grown at a 35.0% compound annual growth rate (CAGR), from $46.02M to $152.71M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Insmed INSM Stock-Based Comp

Stock-Based Comp at other companies

Sarepta Therapeutics, Inc.SRPT

$29.4M-29.0%

United TherapeuticsUTHR

$33.9M+6.6%

Solid Biosciences Inc.SLDB

$5.15M+54.2%

ANI PharmaceuticalsANIP

$10.19M+14.9%

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

SavaraSVRA

$10.73M+261%

Other financials

Income statement

See full

Revenue$306.0M+230%

Gross profit$258.5M+261%

Operating income-$153.3M+38.2%

Net income-$163.6M+36.3%

EPS (diluted)-$0.76+46.5%

Balance sheet

See full

Cash & equivalents$582.2M+44.4%

Total debt$580.3M-49.2%

Total equity$704.9M+611%

Total assets$2.1B+15.2%

Cash flow

See full

Operating cash flow-$222.7M+15.0%

CapEx$3.5M-65.4%

Free cash flow-$226.2M+16.9%

Valuation

See full

Market cap$23.11B+17.6%

Enterprise value$23.11B+22.0%

P/S28.2×-21.1×

Profitability

See full

Gross margin81.8%+5.3pp

Operating margin-140.6%-43.9pp

Net margin-144.4%-45.3pp

FCF margin-112.5%-35.3pp

Returns & leverage

See full

Return on equity-294.5%—

Debt / equity0.8×-10.7×

Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insmed's stock-based comp?: Insmed (INSM) reported stock-based comp of $45.75M in Q1 2026.
How has Insmed's stock-based comp changed year-over-year?: Insmed's stock-based comp increased by 16.5% year-over-year, from $39.26M to $45.75M.
What is the long-term trend for Insmed's stock-based comp?: Over 4 years (2021 to 2025), Insmed's stock-based comp has grown at a 35.0% compound annual growth rate (CAGR), from $46.02M to $152.71M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.